Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L Bakris, Melanie Chin, Heidi Christ-Schmidt, Angie Goldsberry, Mark Houser, Melissa Krauth, Hiddo J Lambers Heerspink, John J McMurray, Colin J Meyer, Hans-Henrik Parving, Giuseppe Remuzzi, Robert D Toto, Nosratola D Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M ChertowBEACON Trial Investigators

    818 Citationer (Scopus)

    Abstract

    Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.
    OriginalsprogEngelsk
    TidsskriftThe New England journal of medicine
    Vol/bind369
    Udgave nummer26
    Sider (fra-til)2492-503
    Antal sider12
    ISSN0028-4793
    DOI
    StatusUdgivet - 26 dec. 2013

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease'. Sammen danner de et unikt fingeraftryk.

    Citationsformater